[ad_1]

HCM is characterized by thickening of the heart muscle, which can disrupt the heart’s electrical rhythm and cause sudden death. Often undiagnosed, it is estimated that 1 in 200 people in the United States have the disease. People of all ages, genders, and races are affected. Medical and surgical treatments can relieve symptoms, but there is no cure and many patients ultimately require a heart transplant.

“In addition to supporting cutting-edge treatments and research to tackle cardiomyopathy, we want to further raise awareness of cardiomyopathy,” said Strauss. “Early detection is key because once you know you have an infection, there are treatments to deal with it.” funding is also essential.”

Bring together talented people

The Cardiomyopathy Precision Medicine Symposium on May 3 will bring together top leaders in cardiomyopathy, including physicians, scientists, and industry leaders, to explore innovations in cardiovascular medicine.

“Treatments have moved from being based on the phenotype, to treating the underlying mechanisms, and more recently to treating the genetic cause or genotype,” said Professor of Medicine and director of the Strauss-Wilson Cardiomyopathy Center. said Eric Adler, MD. Charina and Chancellor Humberto S. López serve as Endowed Chair in Cardiology at the University of California, San Diego School of Medicine and Director of the Division of Heart Failure at the University of California, San Diego School of Health. “We are pleased to bring together such a prestigious group of physicians and researchers to discuss new ideas and drive advances in this field that will impact so many patients around the world.”

[ad_2]

Source link